PSMA-retargeted adenovirus
Generated by an autonomous AI research agent — Anthropic Claude Opus 4.7 or OpenAI GPT-5.5, max reasoning effort. Sources cited inline. Full disclosure at /methodology/jhtv-deep-dive.
Indication
prostate cancer (PSMA-retargeted adenoviral gene therapy)
Modality
Gene Therapy
Mechanism
PSMA-retargeted oncolytic adenovirus
Target
PSMA
rNPV Envelope
Low
-$50.5M
costs +25% · peak −25%
Base
-$39.4M
cumulative PoS 1.5%
High
-$28.3M
costs −25% · peak +25%
This is an illustrative prostate adenoviral-platform envelope. Costs use adenoviral/gene-therapy CMC and intratumoral/systemic delivery complexity; PoS is below standard gene therapy because the actual asset is a retargeting method, not a named clinical candidate.
Composite score breakdown
Locked rubric — 40/30/30 weights
Clinical relevance · 40%
0.50
Modality fit · 30%
0.74
Whitespace · 30%
0.50
Composite 0.572 — composite-score rank #44 of 50 top-tier inventions in the jhtv-portfolio@2026-Q2 cohort. The page header uses rNPV rank (#32) to match the index ordering.
Comparators
Real programs anchoring the engine inputs
PSMA-retargeted adenovirus capsid platform
The direct JHU technology: a phage-derived PSMA-targeting peptide genetically incorporated into adenoviral fiber, selected to preferentially infect PSMA-expressing cells and xenografts.
Criteria 1: exact mechanism; platform rather than final therapeutic product.
CAN-2409 / aglatimagene besadenovec prostate adenoviral immunotherapy
Closest contemporary prostate adenoviral clinical archetype, though it is HSV-tk/prodrug immunotherapy rather than PSMA-retargeted CRAd delivery.
Criteria 2 and 4: same organ and adenoviral platform family; adjacent clinical archetype, not same mechanism.
Oncorine / H101
Approved oncolytic adenovirus archetype establishing that adenoviruses can be regulated as cancer therapeutics, but with narrow regional/indication precedent.
Criteria 3 and 4: adenovirus regulatory archetype; not prostate-specific and not PSMA-retargeted.
Stage profile
Asset-specific cost, duration, and PoS by stage
| Stage | Cost | Duration | PoS | Citations |
|---|---|---|---|---|
| Preclinical | $16.0M | 24 mo | 34.0% | [0] [1] |
| Phase I | $55.0M | 18 mo | 55.0% | [1] [2] |
| Phase II | $120.0M | 30 mo | 23.0% | [1] [2] [3] |
| Phase III | $250.0M | 42 mo | 42.0% | [2] [3] |
| NDA/BLA Review | $16.0M | 12 mo | 84.0% | [2] |
Multiplier handling: Eligible multipliers (targeted_delivery_rationale) are already reflected in Day-1 comparator-calibrated PoS. Re-applying them via log-odds stacking would double-count, so per-stage PoS is taken as final. See methodology for the rule.
Peak revenue and discount rate
$180.0M peak · WACC 15.0%
Peak revenue. As a capsid-retargeting method, value capture would likely be licensing into a partnered adenoviral product. The $180M illustrative peak reflects a niche partnered prostate-virotherapy product-equivalent, not platform-wide revenue.
WACC. Oncolytic/adenoviral prostate delivery remains high-risk and this asset is preclinical platform IP rather than a clinical product.
Sensitivity (tornado)
Top drivers of rNPV variance
Drivers ranked by absolute rNPV swing. The vertical tick inside each bar marks the base rNPV (-$39.4M); each bar spans the rNPV range produced by flexing one input between its low and high values. Gold = the input pushes rNPV up when increased; red = the input pushes rNPV down when increased.
Monte Carlo distribution
1,000 trials · rpNPV mode
This is a bimodal distribution by construction, not a Gaussian. Most paths terminate in clinical failure (red cluster — accumulated cost only); a minority succeed and capture full peak revenue (green tail). Bar heights are square-root-scaled so the success tail stays visible alongside the much taller failure cluster; exact counts are preserved in the percentiles below. Gold line = median (P50). Navy dashed = base rNPV (mean) — the probability-weighted expected value, which can sit above the median when the upper tail is strong enough to outweigh the failure cluster (and close to the median when it isn’t).
P5
-$146.5M
P25
-$56.8M
P50 (median)
-$16.9M
P75
-$9.9M
P95
-$5.3M
Prob ≥ 0
0.4%
Evidence register
4 per-assumption citations
| Assumption | Source | Date | Confidence |
|---|---|---|---|
JHU asset is PSMA-retargeted adenovirus platform cmo_findings.asset_class_reality | PSMA-retargeted adenovirus regulatory | 2014-10-07 | high |
Primary PSMA-retargeted adenovirus publication stage_profile.preclinical.pos | Adenovirus Targeting to Prostate-Specific Membrane Antigen through Virus-Displayed, Semirandom Peptide Library Screening peer_review | 2010-12-01 | high |
Prostate adenoviral clinical archetype comparators[1] | Phase 3 Study of ProstAtak Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer trial_disclosure | 2025-01-01 | high |
Approved adenoviral virotherapy archetype comparators[2] | Oncorine, the World First Oncolytic Virus Medicine and its Update in China peer_review | 2017-11-01 | high |
Thesis
Why this asset earns its rank
This is an enabling retargeted-adenovirus platform, not a finished gene-therapy product. JHU scientists incorporated a PSMA-binding peptide into adenoviral Fiber and selected variants that preferentially infect PSMA-expressing cells and prostate xenografts. The pinned gene_therapy bucket is acceptable for the ranking, but a CMO will read the modality reality as oncolytic/vector retargeting. The rNPV envelope is shown only for cohort consistency - the rNPV is not the decision criterion here, which is why the asset is classified partnership_candidate rather than vc_fundable.
Comparator economics are adjacent, not direct. CAN-2409 shows prostate adenoviral immunotherapy can be clinically developed, and Oncorine shows adenoviral virotherapy has a narrow approval precedent, but neither validates systemic PSMA-retargeted adenovirus as a product. The engine result is -$50.5M to -$28.3M, with a base rNPV of -$39.4M and cumulative PoS of 1.5%; that is a conservative partnered-platform envelope, not a claim of prostate drug ownership.
Verdict: useful targeted-vector IP with clinical-adjacent relevance, but old and preclinical. It earns its rank from PSMA/prostate relevance and the high gene-therapy modality score; the fundable case requires a modern partner to plug the capsid-retargeting method into a real vector payload.
Key risks
Asset-specific, not generic biotech risks
- Modality mismatch: the bucket says gene_therapy, while the asset reality is PSMA-retargeted adenoviral/oncolytic-vector delivery.
- Product-definition risk: no named clinical candidate, payload, dose route, or development indication is defined beyond PSMA-targeted infection.
- Adenovirus systemic-delivery risk: liver sequestration, neutralizing antibodies, and inflammatory toxicity remain core barriers for metastatic prostate use.
- Competitive context: prostate cancer has strong radioligand, AR-axis, PARP, and immunotherapy standards; a vector platform needs a clear niche.